Pin Huang

Title: Innovations by Pin Huang in KRAS Degradation

Introduction

Pin Huang is an accomplished inventor based in Shanghai, China. He has made significant contributions to the field of biotherapeutics, particularly in the development of compounds targeting KRAS mutations. With a total of three patents to his name, Huang's work is paving the way for new treatments in oncology.

Latest Patents

Huang's latest patents include innovative compounds that focus on KRAS degradation. The first patent, titled "Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof," discloses novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities. These compounds are designed for use in pharmaceutical compositions aimed at preventing and treating various diseases and conditions. The second patent, "Glutarimide-containing KRAS-mutant degrader compounds and uses thereof," also relates to glutarimide-containing compounds that specifically target the KRAS mutant form, further expanding the potential for therapeutic applications.

Career Highlights

Huang is currently employed at Tiger Biotherapeutics Inc., where he continues to innovate in the field of biotherapeutics. His work is characterized by a strong focus on developing effective treatments for diseases associated with KRAS mutations. His contributions are vital in the ongoing battle against cancer.

Collaborations

Huang collaborates with notable colleagues, including Robert Luo and Jie Su. Their combined expertise enhances the research and development efforts at Tiger Biotherapeutics Inc., fostering an environment of innovation and discovery.

Conclusion

Pin Huang's work in developing KRAS-targeting compounds represents a significant advancement in biotherapeutics. His patents and collaborations are instrumental in creating new treatment options for patients suffering from KRAS-related diseases.